GILD · 10-Q · 2026Q2 · Full report

Research and Development Expense

GILEAD SCIENCES, INC. · 2026-08-06 · Importance 68 · Surprise 58

Research and development expense increased 18% to $1.8 billion in the second quarter of 2026 and 9% to $3.1 billion for the first six months. Personnel, infrastructure and other support costs increased primarily because of acquisition integration activities. Those costs included $229 million of stock-based compensation related to the Arcellx, Ouro Medicines and Tubulis acquisitions. Clinical studies and other costs declined 3% in both the quarter and year-to-date period because of lower oncology clinical study activity.

Key facts

• Research and development expenses for the six months ended June 30, 2026: $3,136 million. source
• Research and development expenses for the three months ended June 30, 2026: $1,764 million. source
• Personnel, infrastructure and other support costs included $229 million of stock-based compensation expenses related to the acquisitions of Arcellx, Ouro Medicines and Tubulis for the six months ended June 30, 2026. source